Alterity Therapeutics' ATH434 Shows 52% Slowing of Functional Decline in MSA Phase 2 Trial
Event summary
- ATH434 50 mg dose slowed functional decline by 52% vs. placebo in MSA patients at Week 52, adjusting for CSF NfL baseline severity.
- CSF NfL confirmed as a predictive biomarker for disease progression, to be used as a covariate in Phase 3 trials.
- Brain iron MRI data suggests ATH434's mechanism of action, with iron redistribution effects observed in key brain regions.
- Phase 2 trial enrolled 77 MSA patients, with ATH434 showing favorable safety and tolerability profile.
The big picture
Alterity's Phase 2 data positions ATH434 as a potential disease-modifying therapy for MSA, a field with no approved treatments. The validation of CSF NfL as a severity biomarker could set a new standard for MSA clinical trials, while the iron redistribution mechanism offers a novel approach to neurodegenerative disease treatment. The company's progress comes as competition in Parkinsonian disorders intensifies, with several other therapies in mid-to-late stage development.
What we're watching
- Phase 3 Design
- Whether the incorporation of CSF NfL as a covariate will improve trial precision and accelerate regulatory approval.
- Competitive Positioning
- How these results compare to other MSA therapies in development and Alterity's potential first-mover advantage.
- Iron Redistribution Mechanism
- The pace at which MRI evidence of iron redistribution will be further validated as a pharmacodynamic marker.
Related topics